A Phase 1, Open-label Study of the Absorption, Metabolism, and Excretion of [14C]-DNL343 Following a Single Oral Dose in Healthy Male Participants
This is a Phase 1, open-label, nonrandomized, single-dose study in healthy male participants to investigate the absorption, metabolism and excretion of DNL343.
- EligibilityCriteria: Inclusion Criteria:  Males, aged between 18 to 65 years, inclusive Body mass index between 18.0 and 32.0 kg/m2 In good health When engaging in sex with a woman of child bearing potential, both the male participant and his female partner must use highly effective contraception History of a minimum of 1 bowel movement per day  Exclusion Criteria:  History or clinical manifestation of any clinically significant metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder Have a history of malignancy, except fully resected basal cell carcinoma History of significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance History of stomach or intestinal surgery or resection that would potentially alter absorption and/or excretion of orally administered drugs Have previously completed or withdrawn from this study or any other study investigating DNL343 and have previously received DNL343 - HealthyVolunteers: Accepts Healthy Volunteers - Gender: Male - MinimumAge: 18 Years - MaximumAge: 65 Years - StdAgeList: Adult, Older Adult